Repligen (RGEN) 10-Q 2 May 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	Apr. 28, 2023
Cover [Abstract]
Amendment Flag	false
Document Type	10-Q
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Central Index Key	0000730272
Current Fiscal Year End Date	--12-31
Document Period End Date	Mar. 31, 2023
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity File Number	000-14656
Entity Registrant Name	REPLIGEN CORP
Entity Filer Category	Large Accelerated Filer
Trading Symbol	RGEN
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2729386
Entity Address, Address Line One	41 Seyon Street, Bldg. 1, Suite 100
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02453
City Area Code	781
Entity Shell Company	false
Smaller reporting company	false
Emerging growth company	false
Local Phone Number	250-0111
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		55,679,964

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 516,609	$ 523,458
Marketable securities held to maturity	101,409	100,299
Accounts receivable, net of reserves of $1,539 and $1,365 at March 31, 2023 and December 31, 2022, respectively	133,488	116,247
Inventories, net	244,704	238,277
Prepaid expenses and other current assets	22,593	19,837
Total current assets	1,018,803	998,118
Property, plant and equipment, net	192,692	190,673
Intangible assets, net	346,595	353,676
Goodwill	856,301	855,513
Deferred tax assets	845	840
Operating lease right of use assets	121,810	125,023
Other noncurrent assets	1,188	815
Total noncurrent assets	1,519,431	1,526,540
Total assets	2,538,234	2,524,658
Current liabilities:
Accounts payable	26,401	27,554
Operating lease liability	7,959	6,957
Current contingent consideration	27,834	13,950
Accrued liabilities	58,055	71,120
Convertible Senior Notes, net	285,072	284,615
Total current liabilities	405,321	404,196
Deferred tax liabilities	22,050	23,000
Noncurrent operating lease liability	127,665	131,389
Noncurrent contingent consideration	38,910	51,559
Other noncurrent liabilities	3,796	3,814
Total noncurrent liabilities	192,421	209,762
Total liabilities	597,742	613,958
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,644,301 shares at March 31, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding	556	556
Additional paid-in capital	1,544,956	1,547,266
Accumulated other comprehensive loss	(31,121)	(34,394)
Accumulated earnings	426,101	397,272
Total stockholders' equity	1,940,492	1,910,700
Total liabilities and stockholders' equity	$ 2,538,234	$ 2,524,658

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accounts receivable, reserve for doubtful accounts	$ 1,539	$ 1,365
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	55,644,301	55,557,698
Common stock, shares outstanding	55,644,301	55,557,698

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Revenue	$ 182,660	$ 206,400
Costs and operating expenses:
Cost of product revenue	81,845	82,356
Research and development	12,154	12,155
Selling, general and administrative	56,170	54,300
Contingent consideration	1,235	(2,411)
Total costs and operating expenses	151,404	146,400
Income from operations	31,256	60,000
Other income (expenses):
Investment income	5,486	77
Interest expense	(270)	(292)
Amortization of debt issuance costs	(457)	(452)
Other income (expenses)	77	(402)
Other income (expenses), net	4,836	(1,069)
Income before income taxes	36,092	58,931
Income tax provision	7,263	11,967
Net income	$ 28,829	$ 46,964
Earnings per share:
Basic	$ 0.52	$ 0.85
Diluted (Note 10)	$ 0.51	$ 0.81
Weighted average common shares outstanding:
Basic	55,590	55,353
Diluted (Note 10)	57,049	58,816
Net income	$ 28,829	$ 46,964
Other comprehensive income (loss):
Foreign currency translation adjustment	3,273	(4,688)
Comprehensive income	32,102	42,276
Products
Revenue:
Revenue	182,621	206,363
Royalty and other revenue
Revenue:
Revenue	$ 39	$ 37

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings
Balance at Dec. 31, 2021	$ 1,750,067	$ 553	$ 1,572,340	$ (16,886)	$ 194,060
Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021	(21,817)		(39,070)		17,253
Beginning Balance (in shares) at Dec. 31, 2021		55,321,457
Net income	46,964				46,964
Issuance of common stock for debt conversion	(2)	$ 0	(2)
Issuance of common stock for debt conversion (in shares)		8
Exercise of stock options and vesting of stock units	297	$ 2	295
Exercise of stock options and vesting of stock units (in shares)		170,990
Tax withholding on vesting of restricted stock units	(12,311)	$ (1)	(12,310)
Tax withholding on vesting of restricted stock units (in shares)		(63,409)
Stock-based compensation expense	7,915		7,915
Other	(24)		(24)
Balance at Mar. 31, 2022	1,766,401	$ 554	1,529,144	(21,574)	258,277
Ending Balance (in shares) at Mar. 31, 2022		55,429,046
Translation adjustment	(4,688)			(4,688)
Balance at Dec. 31, 2022	1,910,700	$ 556	1,547,266	(34,394)	397,272
Beginning Balance (in shares) at Dec. 31, 2022		55,557,698
Net income	28,829				28,829
Exercise of stock options and vesting of stock units	29	$ 1	28
Exercise of stock options and vesting of stock units (in shares)		140,210
Tax withholding on vesting of restricted stock units	(9,592)	$ (1)	(9,592)
Tax withholding on vesting of restricted stock units (in shares)		(53,607)
Stock-based compensation expense	7,254		7,254
Balance at Mar. 31, 2023	1,940,492	$ 556	$ 1,544,956	(31,121)	$ 426,101
Ending Balance (in shares) at Mar. 31, 2023		55,644,301
Translation adjustment	$ 3,273			$ 3,273

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net income	$ 28,829	$ 46,964
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	15,252	11,834
Amortization of debt issuance costs	457	452
Stock-based compensation	7,254	7,915
Deferred income taxes, net	(1,124)	1,045
Contingent consideration	1,235	(2,411)
Other	(857)	73
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(16,832)	(6,269)
Inventories	(5,845)	(30,037)
Prepaid expenses and other assets	(2,799)	283
Operating lease right of use assets	3,349	1,514
Other assets	(434)	(204)
Accounts payable	(1,194)	2,200
Accrued expenses	(13,326)	(9,999)
Operating lease Liabilities	(2,870)	(17)
Long-term liabilities	59	(230)
Total cash provided by operating activities	11,154	23,113
Cash flows from investing activities:
Additions to capitalized software costs	(924)	(1,027)
Purchases of property, plant and equipment	(8,509)	(27,204)
Other investing activities	0	17
Total cash used in investing activities	(9,433)	(28,214)
Cash flows from financing activities:
Proceeds from exercise of stock options	29	296
Payment of tax withholding obligation on vesting of restricted stock	(9,592)	(12,311)
Repayment of Convertible Senior Notes	0	(6)
Total cash used in financing activities	(9,563)	(12,021)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	993	(2,052)
Net decrease in cash, cash equivalents and restricted cash	(6,849)	(19,174)
Cash, cash equivalents and restricted cash, beginning of period	523,458	603,814
Cash and cash equivalents, end of period	516,609	584,640
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	$ 179	$ 1,119

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company”, “Repligen”, “our” or “we”) in accordance with generally accepted accounting principles accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 22, 2023 (“Form 10-K”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The business and economic uncertainty resulting from government-mandated actions in response to the COVID-19 pandemic, including all subsequent variants of the SARS-CoV-2 coronavirus ("COVID-19"), the Russia-Ukraine conflict, supply chain challenges, cost pressure and the overall effects of the current high inflation environment on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB, Repligen GmbH, Spectrum ® LifeSciences LLC and its subsidiaries (“Spectrum”), C Technologies, Inc., ARTeSYN Biosolutions Holdings Ireland Ltd., ARTeSYN Biosolutions Ireland Limited and its subsidiaries ("ARTeSYN"), Polymem S.A. (“Polymem”), Avitide LLC ("Avitide"), Newton T&M Corp. ("NTM"), Bio-Flex Solutions, L.L.C. ("BioFlex"), Repligen Singapore Pte. Ltd. and Repligen UK Limited. All significant intercompany accounts and transactions have been eliminated in consolidation. Except for the change in the Company's policy on Convertible Senior Notes, which the Company adopted effective January 1, 2022 as required by Accounting Standards Update No. ("ASU" or "ASUs") 2020-06 and discussed in Note 6, "Convertible Senior Notes," to these condensed consolidated financial statements, the Company made no material changes in the application of its significant accounting policies that were disclosed in its Form 10-K. In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of its financial position as of March 31, 2023, its results of operations for the three months ended March 31, 2023 and 2022 and cash flows for the three months ended March 31, 2023 and 2022 . The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year. Certain prior year balances have been reclassified to conform to current year presentation. Recent Accounting Standards Updates We consider the applicability and impact of all ASUs on the Company’s condensed consolidated financial statements. As of March 31, 2023, there were no accounting standards or ASUs recently issued or effective during the fiscal year that would have a material effect on the Company's condensed consolidated financial statements or disclosures.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Disclosure Text Block [Abstract]
Fair Value Measurements	2. Fair Value Measurements The Company uses various valuation approaches in determining the fair value of its assets and liabilities. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access Level 2 - Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. Cash, Cash Equivalents and Marketable Securities Held to Maturity The following table summarizes the Company's cash, cash equivalents and marketable securities held to maturity as of March 31, 2023 and December 31, 2022 (amounts in thousands): As of March 31, 2023 Amortized Gross Gross Estimated Cash and cash equivalents: Cash and money market funds $ 516,609 $ — $ — $ 516,609 Total cash and cash equivalents 516,609 — — 516,609 Marketable securities held to maturity: U.S. treasury bills - short-term 101,409 58 — 101,467 Total cash, cash equivalents and marketable securities $ 618,018 $ 58 $ — $ 618,076 As of December 31, 2022 Amortized Gross Gross Estimated Cash and cash equivalents: Cash and money market funds $ 523,458 $ — $ — $ 523,458 Total cash and cash equivalents 523,458 — — 523,458 Marketable securities held to maturity: U.S. treasury bills - short-term 100,299 24 — 100,323 Total cash, cash equivalents and marketable securities $ 623,757 $ 24 $ — $ 623,781 During the fourth quarter of 2022, the Company purchased $ 100.0 million of 6-month U.S. treasury bills with the positive intent and ability to hold them until maturity. Therefore, the Company classified this investment as held to maturity and stated it at amortized cost on the condensed consolidated balance sheet. The amortized cost and the fair value of the Company's held to maturity securities by contractual maturity at March 31, 2023 and December 31, 2022 are summarized below: March 31, 2023 December 31, 2022 Amortized Estimated Amortized Estimated Maturity of one year or less $ 101,409 $ 101,467 $ 100,299 $ 100,323 Total $ 101,409 $ 101,467 $ 100,299 $ 100,323 Fair Value Measured on a Recurring Basis Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 31, 2023 and December 31, 2022 (amounts in thousands): As of March 31, 2023 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 339,044 $ — $ — $ 339,044 Liabilities: Short-term contingent consideration (1) $ — $ — $ 27,834 $ 27,834 Long-term contingent consideration $ — $ — $ 38,910 $ 38,910 As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 343,929 $ — $ — $ 343,929 Liabilities: Short-term contingent consideration $ — $ — $ 13,950 $ 13,950 Long-term contingent consideration $ — $ — $ 51,559 $ 51,559 (1) The $ 27.8 million of short-term contingent consideration includes $ 14.5 million due and payable to the remaining securityholders of Avitide related to the First Earnout Year as defined in the Agreement and Plan of Merger and Reorganization with Avalon Merger Sub, Inc., which the Company entered into as part of the acquisition of Avitide in 2021. This amount is anticipated to be paid in the second quarter of 2023. Contingent Consideration – Earnout As of March 31, 2023 , the maximum amount of future contingent consideration (undiscounted) that we could be required to pay in connection with the completed acquisition of Avitide, was $ 125.0 million. Refer to Note 4, "Acquisitions" included in Part II, Item 8, “ Financial Statements and Supplementary Data” to our Form 10-K for additional information on the contingent consideration. During 2023, a change in market inputs used to calculate the discount rate resulted in an increase in amounts reported as of March 31, 2023 . A reconciliation of the change in the fair value of contingent consideration - earnout is included in the following table (amounts in thousands): Balance at December 31, 2022 $ 65,509 Increase in fair value of contingent consideration earnouts 1,235 Balance at March 31, 2023 $ 66,744 The recurring Level 3 fair value measurement of our contingent consideration earnout that we expect to be required to settle our 2023 and 2024 contingent consideration obligation include the following significant unobservable inputs (amounts in thousands, except percent data): Contingent Consideration Earnout Fair Value as of Valuation Technique Unobservable Input Range Weighted Average (1) Probability of Commercialization-based Monte Carlo Success 100 % 100 % payments $ 18,974 Simulation Earnout Discount Rate 5.9 %- 6.1 % 6.0 % Volatility 23.6 % 23.6 % Revenue and Volume- Monte Carlo Revenue & Volume based payments $ 33,301 Simulation Discount Rate 6.4 % 6.4 % Earnout Discount Rate 5.9 %- 6.1 % 6.0 % (1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. Fair Value Measured on a Nonrecurring Basis During the three months ended March 31, 2023 , there were no re-measurements to the fair value of financial assets and liabilities that are measured at fair value on a nonrecurring basis.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Revenue Recognition	3. Revenue Recognition Disaggregation of Revenue Revenues for the three months ended March 31, 2023 and 2022 were as follows: Three Months Ended 2023 2022 (Amounts in thousands) Product revenue $ 182,621 $ 206,363 Royalty and other income 39 37 Total revenue $ 182,660 $ 206,400 When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because substantially all of its revenues are from bioprocessing customers, there are no differences in the nature, timing and uncertainty of the Company’s revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, regulatory, economic and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. In addition, a significant portion of the Company’s revenue is generated from a small number of customers; therefore, economic factors specific to these customers could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Disaggregated revenue from contracts with customers by geographic region and revenue from significant customers can be found in Note 12, “Segment Reporting,” included in this report. For more information regarding our product revenue, see Note 6, “Revenue Recognition” included in Part II, Item 8, “ Financial Statements and Supplementary Data” to our Form 10-K. Contract Balances from Contracts with Customers The following table provides information about receivables and deferred revenue from contracts with customers as of March 31, 2023 (amounts in thousands): March 31, December 31, 2023 2022 Balances from contracts with customers only: Accounts receivable $ 133,488 $ 116,247 Deferred revenue (included in accrued liabilities and $ 18,821 $ 19,631 Revenue recognized during periods presented relating to: The beginning deferred revenue balance $ 8,601 $ 13,390 The timing of revenue recognition, billings and cash collections results in the accounts receivable and deferred revenue balances on the Company’s condensed consolidated balance sheets.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2023
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	4. Goodwill and Intangible Assets Goodwill The following table represents the change in the carrying value of goodwill for the three months ended March 31, 2023 (amounts in thousands): Balance at December 31, 2022 $ 855,513 Cumulative translation adjustment 788 Balance at March 31, 2023 $ 856,301 During each of the fourth quarters of 2022, 2021 and 2020, the Company completed its annual impairment assessments and concluded that goodwill was not impaired in any of those years. The Company has not identified any “triggering” events which indicate an impairment of goodwill in the three months ended March 31, 2023. Intangible Assets Indefinite-lived intangible assets are reviewed for impairment at least annually. There has been no impairment of the Company’s intangible assets for the periods presented. Intangible assets, net, consisted of the following at March 31, 2023: March 31, 2023 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology - developed $ 190,620 $ ( 33,983 ) $ 156,637 16 Patents 240 ( 240 ) — 8 Customer relationships 253,181 ( 70,844 ) 182,337 16 Trademarks 7,687 ( 1,431 ) 6,256 19 Other intangibles 2,819 ( 2,154 ) 665 4 Total finite-lived intangible assets 454,547 ( 108,652 ) 345,895 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 455,247 $ ( 108,652 ) $ 346,595 Intangible assets, net, consisted of the following at December 31, 2022: December 31, 2022 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology - developed $ 190,463 $ ( 30,992 ) $ 159,471 16 Patents 240 ( 240 ) — 8 Customer relationships 252,934 ( 66,559 ) 186,375 15 Trademarks 7,682 ( 1,319 ) 6,363 19 Other intangibles 2,811 ( 2,044 ) 767 4 Total finite-lived intangible assets 454,130 ( 101,154 ) 352,976 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 454,830 $ ( 101,154 ) $ 353,676 Amortization expense for finite-lived intangible assets was $ 7.4 million and $ 6.6 million for the three months ended March 31, 2023 and 2022 , respectively. As of March 31, 2023, the Company expects to record the following amortization expense in future periods (amounts in thousands): Estimated Amortization For the Years Ended December 31, Expense 2023 (remaining nine months) $ 22,073 2024 28,628 2025 28,370 2026 28,388 2027 28,302 2028 and thereafter 210,134 Total $ 345,895

Consolidated Balance Sheet Deta

Consolidated Balance Sheet Detail	3 Months Ended
	Mar. 31, 2023
Disclosure Text Block [Abstract]
Consolidated Balance Sheet Detail	5. Consolidated Balance Sheet Detail Inventories, net Inventories, net consists of the following: March 31, December 31, 2023 2022 (Amounts in thousands) Raw materials $ 150,398 $ 149,438 Work-in-process 6,277 6,183 Finished products 88,029 82,656 Total inventories, net $ 244,704 $ 238,277 Property, Plant and Equipment Property, plant and equipment consist of the following: March 31, December 31, 2023 2022 (Amounts in thousands) Land $ 1,006 $ 1,003 Buildings 1,657 1,599 Leasehold improvements 120,361 115,672 Equipment 99,051 94,613 Furniture, fixtures and office equipment 8,447 8,307 Computer hardware and software 31,226 29,813 Construction in progress 30,891 31,553 Other 429 420 Total property, plant and equipment 293,068 282,980 Less - Accumulated depreciation ( 100,376 ) ( 92,307 ) Total property, plant and equipment, net $ 192,692 $ 190,673 Accrued Liabilities Accrued liabilities consist of the following: March 31, December 31, 2023 2022 (Amounts in thousands) Employee compensation $ 20,592 $ 33,522 Deferred revenue 18,378 19,283 Income taxes payable 2,747 2,459 Other 16,338 15,856 Total accrued liabilities $ 58,055 $ 71,120

Convertible Senior Notes

Convertible Senior Notes	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Convertible Senior Notes	6. Convertible Senior Notes 0.375% Convertible Senior Notes due 2024 On July 19, 2019, the Company issued $ 287.5 million aggregate principal pursuant to the 2019 Notes, which includes the underwriters’ exercise in full of an option to purchase an additional $ 37.5 million aggregate principal amount of 2019 Notes (the “Notes Offering”). The net proceeds of the Notes Offering, after deducting underwriting discounts and commissions and other related offering expenses payable by the Company, were approximately $ 278.5 million. The 2019 Notes are senior, unsecured obligations of the Company, and bear interest at a rate of 0.375 % per year. Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The 2019 Notes will mature on July 15, 2024 , unless earlier repurchased or converted in accordance with their terms. During the first quarter of 2023, the closing price of the Company’s common stock exceeded 130 % of the conversion price of the 2019 Notes for more than 20 trading days of the last 30 consecutive trading days of the quarter. As a result, the 2019 Notes are convertible at the option of the holders of the 2019 Notes during the second quarter of 2023, the quarter immediately following the quarter when the conditions are met, as stated in the terms of the 2019 Notes. These conditions have been met each quarter since the third quarter of 2020. As a result, $ 39,000 aggregate principal amount of the 2019 Notes have been requested for conversion by the note holders since the issuance of the 2019 Notes, all conversions have settled except for $ 9,000 aggregate principal amount, which settles in the second quarter of 2023. The conversions resulted in the issuance of a nominal number of shares of the Company’s common stock to the note holders. The Company continues to classify the carrying value of the 2019 Notes as current liabilities on the Company’s condensed consolidated balance sheets at March 31, 2023. The net carrying value of the liability component of the 2019 Notes is as follows: March 31, December 31, (Amounts in thousands) 0.375% Convertible Senior Notes due 2024: Principal amount $ 287,470 $ 287,470 Unamortized debt issuance costs ( 2,398 ) ( 2,855 ) Net carrying amount $ 285,072 $ 284,615 The following table sets forth total interest expense recognized related to the 2019 Notes: Three Months Ended 2023 2022 (Amounts in thousands) Contractual interest expense $ 270 $ 270 Amortization of debt issuance costs 457 452 Total $ 727 $ 722 Effective interest rate of the liability component 1 % 1 % At March 31, 2023 and December 31, 2022, the carrying value of the 2019 Notes was $ 285.1 million and $ 284.6 million, respectively, net of unamortized discount, and the fair value of the 2019 Notes was $ 441.8 million and $ 452.0 million, respectively. The fair value of the 2019 Notes was determined based on the most recent trade activity of the 2019 Notes at March 31, 2023 and December 31, 2022 .

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stockholders' Equity	7. Stockholders’ Equity Stock Option and Incentive Plans Under the Company’s current 2018 Stock Option and Incentive Plan (the “2018 Plan”), the number of shares of the Company’s common stock that were reserved and available for issuance is 2,778,000 , plus the number of shares of common stock that were available for issuance under the Company’s previous equity plans. The shares of common stock underlying any awards under the 2018 Plan and previous equity plans (together, the “Plans”) that are forfeited, canceled or otherwise terminated (other than by exercise) shall be added back to the shares of stock available for issuance under the 2018 Plan. At March 31, 2023, 1,739,335 shares were available for future grants under the 2018 Plan. Stock-Based Compensation The following table presents stock-based compensation expense in the Company’s condensed consolidated statements of comprehensive income: Three Months Ended 2023 2022 (Amounts in thousands) Cost of product revenue $ 591 $ 622 Research and development 787 799 Selling, general and administrative 5,876 6,494 Total stock-based compensation $ 7,254 $ 7,915 Stock Options Information regarding option activity for the three months ended March 31, 2023 under the Plans is summarized below: Shares Weighted Weighted- Aggregate Options outstanding at December 31, 2022 609,965 $ 71.74 Granted 42,982 $ 181.03 Exercised ( 1,300 ) $ 22.41 Forfeited/expired/cancelled ( 2,000 ) $ 199.71 Options outstanding at March 31, 2023 649,647 $ 78.68 Options exercisable at March 31, 2023 374,084 $ 54.57 Vested and expected to vest at March 31, 2023 (1) 633,533 $ 78.10 5.91 $ 60,647 (1) Represents the number of vested options as of March 31, 2023 plus the number of unvested options expected to vest as of March 31, 2023 based on the unvested outstanding options at March 31, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees. The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on March 31, 2023, the last business day of the first quarter of 2023, of $ 168.36 per share and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on March 31, 2023. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2023 and 2022 was $ 0.2 million and $ 1.4 million, respectively. The weighted average grant date fair value of options granted during the three months ended March 31, 2023 and 2022 was $ 89.25 and $ 79.96 , respectively. Stock Units The fair value of stock units is calculated using the closing price of the Company’s common stock on the date of grant. The Company recognizes expense on awards with service-based vesting over the employee’s requisite service period on a straight-line basis. The Company recognizes expense on performance-based awards over the vesting period based on the probability that the performance metrics will be achieved. Information regarding stock unit activity, which includes activity for RSUs and performance stock units, for the three months ended March 31, 2023 under the Plans is summarized below: Shares Weighted Average Unvested at December 31, 2022 531,034 $ 142.57 Awarded 130,929 $ 180.05 Vested ( 123,938 ) $ 118.33 Forfeited/cancelled ( 21,529 ) $ 195.74 Unvested at March 31, 2023 516,496 $ 154.72 Vested and expected to vest at March 31, 2023 (1) 479,766 $ 153.33 (1) Represents the number of vested stock units as of March 31, 2023 plus the number of unvested stock units expected to vest as of March 31, 2023 based on the unvested outstanding stock units at March 31, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees. The aggregate intrinsic value of stock units vested during the three months ended March 31, 2023 and 2022 was $ 24.3 million and $ 30.2 million, respectively. The weighted average grant date fair value of stock units granted during the three months ended March 31, 2023 and 2022 was $ 180.05 and $ 196.36 , respectively. As of March 31, 2023, there was $ 81.4 million of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 3.07 years. The Company expects 2,166,862 unvested options and stock units to vest over the next five years .

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Collaboration Agreements The Company licenses certain technologies that are, or may be, incorporated into its technology under several agreements and also has entered into several clinical research agreements that require the Company to fund certain research projects. Generally, the license agreements require the Company to pay annual maintenance fees and royalties on product sales once a product has been established using the technologies. Research and development expenses associated with license agreements were immaterial amounts for the three months ended March 31, 2023 and 2022. In June 2018, the Company secured an agreement with Navigo Proteins GmbH (“Navigo”) for the exclusive co-development of multiple affinity ligands for which the Company holds commercialization rights. The Company is manufacturing and supplying the first of these ligands, NGL-Impact ® , exclusively to Purolite Life Sciences, an Ecolab Inc. company (“Purolite”), who is pairing the Company’s high-performance ligand with Purolite’s agarose jetting base bead technology used in their Jetted A50 Protein A resin product. The Company also signed a long-term supply agreement with Purolite for NGL-Impact and other potential additional affinity ligands that may advance from the Company’s Navigo collaboration. In September 2020, the Company and Navigo successfully completed co-development of an affinity ligand targeting the SARS-CoV-2 spike protein, to be utilized in the purification of vaccines for the COVID-19 pandemic, including emerging variants of the SARS-CoV-2 coronavirus. The Company has proceeded with scaling up and manufacturing this ligand and the development and validation of the related affinity chromatography resin, which is marketed by the Company. In September 2021, the Company and Navigo successfully completed co-development of a novel affinity ligand that addresses aggregation issues associated with pH sensitive antibodies and Fc-fusion proteins. The Company is manufacturing and supplying this ligand, NGL-Impact ® HipH, to Purolite. The Navigo and Purolite agreements are supportive of the Company’s strategy to secure and reinforce the Company’s proteins business. The Company made royalty payments to Navigo of $ 1.1 million and $ 0.4 million for the three months ended March 31, 2023 and 2022, respectively. Legal Proceedings From time to time, in the normal course of its operations, the Company is subject to litigation matters and claims relating to employee relations, business practices and patent infringement. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict, and the Company's view of these matters may change in the future as the litigation and events related thereto unfold. The Company expenses legal fees as incurred. The Company records a provision for contingent losses when it is both probably that a liability has been incurred and the amount of the loss can be reasonably estimated. An unfavorable outcome to any legal matter, if material, could have an adverse effect on the Company's operations or its financial results.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes For the three months ended March 31, 2023 and 2022, the Company recorded an income tax provision of $ 7.3 million and $ 12.0 million, respectively. The Company’s effective tax rate for the three months ended March 31, 2023 and 2022 was 20.1 % and 20.3 % , respectively. The decrease in effective tax rates between the periods was primarily due to lower income before taxes and increased benefits from business tax credits and windfall benefits recognized on stock option exercises and the vesting of stock units, partially offset by nondeductible contingent consideration and lower foreign-derived intangible income. On August 16, 2022, the United States enacted the Inflation Reduction Act of 2022 ("Inflation Reduction Act"), which, among other things, implements a 15 % alternative minimum tax on global adjusted financial statement income of certain large corporations, a 1 % excise tax on net stock repurchases and several tax incentives to promote clean energy and was effective beginning in 2023. We evaluated the provisions of the Inflation Reduction Act and no provision had a material effect on our consolidation financial position or results of operations.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share, Basic [Abstract]
Earnings Per Share	10. Earnings Per Share A reconciliation of basic and diluted weighted average shares outstanding is as follows: Three Months Ended 2023 2022 (Amounts in thousands, Numerator: Net income $ 28,829 $ 46,964 Effect of dilutive securities: Charges associated with convertible debt instruments, net of tax — 387 Numerator for diluted earnings per share - net income available to common $ 28,829 $ 47,351 Denominator: Weighted average shares used in computing net income per share - basic 55,590 55,353 Effect of dilutive shares: Options and stock units 529 726 Convertible senior notes 883 2,726 Contingent consideration 44 — Dilutive effect of unvested performance stock units 3 11 Dilutive potential common shares 1,459 3,463 Denominator for diluted earnings per share - adjusted weighted average 57,049 58,816 Earnings per share: Basic $ 0.52 $ 0.85 Diluted $ 0.51 $ 0.81 For the three months ended March 31, 2023 and 2022, 263,871 shares and 137,247 shares, respectively, of the Company’s common stock were excluded from the calculation of diluted EPS because the exercise prices of the stock options were greater than or equal to the average price of the common shares and were therefore anti-dilutive. In July 2019, the Company issued $ 287.5 million aggregate principal amount of the 2019 Notes. As provided by the terms of the indenture underlying the 2019 Notes, prior to March 4, 2022, conversion of the 2019 Notes could have been settled in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. On March 4, 2022, we entered into the Second Supplemental Indenture for the 2019 Notes, which irrevocably elected to settle the conversion of the 2019 Notes using a combination of cash and shares of the Company’s common stock, settling the par value of the 2019 Notes in cash and any excess conversion premium in shares. As provided by the terms of the Second Supplemental Indenture underlying the 2019 Notes, the Company irrevocably elected to settle the conversion obligation for the 2019 Notes in a combination of cash and shares of the Company's common stock. This means the Company will settle the par value of the 2019 Notes in cash and any excess conversion premium in shares. The Company adopted ASU 2020-06 effective January 1, 2022. Under ASU 2020-06, the Company is required to reflect the dilutive effect of the convertible securities by application of the "if-converted" method, which means the denominator of the EPS calculation would include the total number of shares assuming the 2019 Notes had been fully converted at the beginning of the period. Prior to March 4, 2022, the Company had the choice to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 (the date the Company adopted ASU 2020-06) to March 4, 2022, the Company included 3,474,429 shares in the denominator of the EPS calculation, applying the if converted method. Subsequent to March 4, 2022, after the Second Supplemental Indenture became effective, the Company irrevocably elected to settle the conversion obligation for the 2019 Notes in a combination of cash and shares of the Company's common stock, and from March 5, 2022 forward, only the excess premium will be settled with shares. Under the if-converted method of calculating dilutive shares, the Company was also required to exclude amortization of debt issuance costs and interest charges applicable to the convertible debt from the numerator of the dilutive EPS calculation for the period from January 1, 2022 to March 4, 2022, as if the interest on convertible debt was never recognized for that period. For the three months ended March 31, 2022, the Company excluded interest charges of $ 0.4 million (net of tax) from the numerator. Prior to the adoption of ASU 2020-06, the Company applied the provisions of ASC 260, “Earnings Per Share,” Subsection 10-45-44, to determine the diluted weighted average shares outstanding as it related to the conversion spread on its convertible notes. Accordingly, the par value of the 2019 Notes was not included in the calculation of diluted income per share, but the dilutive effect of the conversion premium was considered in the calculation of diluted net income per share using the treasury stock method. The dilutive impact of the 2019 Notes was based on the difference between the Company’s current period average stock price and the conversion price of the 2019 Notes, provided there was a premium. Pursuant to this accounting standard, there was no dilution from the accreted principal of the 2019 Notes. For the three months ended March 31, 2023, the dilutive effect of the conversion premium included in the calculation of diluted earnings was 882,599 shares. For the three months ended March 31, 2022, the dilutive effect of the conversion premium included in the calculation of diluted earnings was 2,726,258 shares.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions Certain facilities leased by Spectrum are owned by the Roy T. Eddleman Living Trust (the "Trust"). As of March 31, 2023 , the Trust owned greater than 5 % of the Company’s outstanding shares. Therefore, the Company considers the Trust to be a related party. The lease amounts paid to the Trust prior to the public offering were negotiated in connection with the acquisition of Spectrum. The Company incurred rent expense totaling $ 0.2 million for each of the three months ended March 31, 2023 and 2022 related to these leases.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Reporting	12. Segment Reporting The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended March 31, 2023 2022 Revenue by customers' geographic locations: North America 38 % 40 % Europe 39 % 43 % APAC/Other 23 % 17 % Total revenue 100 % 100 % Concentrations of Credit Risk and Significant Customers Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company’s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings and credit exposure to any one issue, issuer (with the exception of U.S. Treasury obligations) and type of instrument is limited. At March 31, 2023 and December 31, 2022, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements. Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential write-off of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition. Revenue from sales to Pfizer, Inc. were $ 20.1 million, or 11.0 % and $ 21.1 million, or 10.2 % of the Company's total revenue for the three months ended March 31, 2023 and 2022, respectively. Significant accounts receivable balances representing 10 % or more of the Company’s total trade accounts receivable and royalties at March 31, 2023 came from our accounts receivable balance outstanding with Pfizer Inc., which was 14.7 % of our total accounts receivable and other receivable balance. Significant accounts receivable balances representing 10 % or more of the Company’s total trade accounts receivable and royalties at December 31, 2022 came from our accounts receivable balance outstanding with Purolite (an Ecolab Inc. company), which was 12.7 % of our total accounts receivable and other receivable balance.

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Event	13. Subsequent Event Acquisition of FlexBiosys, Inc. On April 17, 2023 , the Company completed its acquisition of all of the outstanding equity interests in FlexBiosys, Inc. ("FlexBiosys"), pursuant to an Equity Purchase Agreement ("EPA") with FlexBiosys, TSAP Holdings Inc. ("NJ Seller"), Gayle Tarry and Stanley Tarry, as individuals (collectively with NJ Seller, the "Sellers"), and Stanley Tarry, in his capacity as the representative of the Sellers. FlexBiosys, which is headquartered in Branchburg, New Jersey, offers expert design and custom manufacturing of single-use bioprocessing products and a comprehensive range of products that include bioprocessing bags, bottles, and tubing assemblies. These products will complement and expand our fluid management portfolio of offerings. The Company will account for the FlexBiosys Acquisition as a purchase of a business under the acquisition method of accounting and has engaged a third-party valuation firm to assist with the valuation of the business acquired. The required disclosures under ASC 805, "Business Combinations" will be included in the Quarterly Report on Form 10-Q for the period ended June 30, 2023.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of presentation	Basis of Presentation The condensed consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company”, “Repligen”, “our” or “we”) in accordance with generally accepted accounting principles accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 22, 2023 (“Form 10-K”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The business and economic uncertainty resulting from government-mandated actions in response to the COVID-19 pandemic, including all subsequent variants of the SARS-CoV-2 coronavirus ("COVID-19"), the Russia-Ukraine conflict, supply chain challenges, cost pressure and the overall effects of the current high inflation environment on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB, Repligen GmbH, Spectrum ® LifeSciences LLC and its subsidiaries (“Spectrum”), C Technologies, Inc., ARTeSYN Biosolutions Holdings Ireland Ltd., ARTeSYN Biosolutions Ireland Limited and its subsidiaries ("ARTeSYN"), Polymem S.A. (“Polymem”), Avitide LLC ("Avitide"), Newton T&M Corp. ("NTM"), Bio-Flex Solutions, L.L.C. ("BioFlex"), Repligen Singapore Pte. Ltd. and Repligen UK Limited. All significant intercompany accounts and transactions have been eliminated in consolidation. Except for the change in the Company's policy on Convertible Senior Notes, which the Company adopted effective January 1, 2022 as required by Accounting Standards Update No. ("ASU" or "ASUs") 2020-06 and discussed in Note 6, "Convertible Senior Notes," to these condensed consolidated financial statements, the Company made no material changes in the application of its significant accounting policies that were disclosed in its Form 10-K. In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of its financial position as of March 31, 2023, its results of operations for the three months ended March 31, 2023 and 2022 and cash flows for the three months ended March 31, 2023 and 2022 . The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year. Certain prior year balances have been reclassified to conform to current year presentation.
Recent Accounting Standards Updates	Recent Accounting Standards Updates We consider the applicability and impact of all ASUs on the Company’s condensed consolidated financial statements. As of March 31, 2023, there were no accounting standards or ASUs recently issued or effective during the fiscal year that would have a material effect on the Company's condensed consolidated financial statements or disclosures.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Summary of Cash, Cash Equivalents and Marketable Securities Held to Maturity	The following table summarizes the Company's cash, cash equivalents and marketable securities held to maturity as of March 31, 2023 and December 31, 2022 (amounts in thousands): As of March 31, 2023 Amortized Gross Gross Estimated Cash and cash equivalents: Cash and money market funds $ 516,609 $ — $ — $ 516,609 Total cash and cash equivalents 516,609 — — 516,609 Marketable securities held to maturity: U.S. treasury bills - short-term 101,409 58 — 101,467 Total cash, cash equivalents and marketable securities $ 618,018 $ 58 $ — $ 618,076 As of December 31, 2022 Amortized Gross Gross Estimated Cash and cash equivalents: Cash and money market funds $ 523,458 $ — $ — $ 523,458 Total cash and cash equivalents 523,458 — — 523,458 Marketable securities held to maturity: U.S. treasury bills - short-term 100,299 24 — 100,323 Total cash, cash equivalents and marketable securities $ 623,757 $ 24 $ — $ 623,781
Schedule of Amortized Cost and Fair Value Held to Maturity Securities by Contractual Maturity	The amortized cost and the fair value of the Company's held to maturity securities by contractual maturity at March 31, 2023 and December 31, 2022 are summarized below: March 31, 2023 December 31, 2022 Amortized Estimated Amortized Estimated Maturity of one year or less $ 101,409 $ 101,467 $ 100,299 $ 100,323 Total $ 101,409 $ 101,467 $ 100,299 $ 100,323
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 31, 2023 and December 31, 2022 (amounts in thousands): As of March 31, 2023 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 339,044 $ — $ — $ 339,044 Liabilities: Short-term contingent consideration (1) $ — $ — $ 27,834 $ 27,834 Long-term contingent consideration $ — $ — $ 38,910 $ 38,910 As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 343,929 $ — $ — $ 343,929 Liabilities: Short-term contingent consideration $ — $ — $ 13,950 $ 13,950 Long-term contingent consideration $ — $ — $ 51,559 $ 51,559 (1) The $ 27.8 million of short-term contingent consideration includes $ 14.5 million due and payable to the remaining securityholders of Avitide related to the First Earnout Year as defined in the Agreement and Plan of Merger and Reorganization with Avalon Merger Sub, Inc., which the Company entered into as part of the acquisition of Avitide in 2021. This amount is anticipated to be paid in the second quarter of 2023.
Schedule of Reconciliation of the Change in the Fair Value of Contingent Consideration - Earnout	A reconciliation of the change in the fair value of contingent consideration - earnout is included in the following table (amounts in thousands): Balance at December 31, 2022 $ 65,509 Increase in fair value of contingent consideration earnouts 1,235 Balance at March 31, 2023 $ 66,744
Schedule of Contingent Consideration Earnout Expect to be Required to Settle Include Significant Unobservable Inputs	The recurring Level 3 fair value measurement of our contingent consideration earnout that we expect to be required to settle our 2023 and 2024 contingent consideration obligation include the following significant unobservable inputs (amounts in thousands, except percent data): Contingent Consideration Earnout Fair Value as of Valuation Technique Unobservable Input Range Weighted Average (1) Probability of Commercialization-based Monte Carlo Success 100 % 100 % payments $ 18,974 Simulation Earnout Discount Rate 5.9 %- 6.1 % 6.0 % Volatility 23.6 % 23.6 % Revenue and Volume- Monte Carlo Revenue & Volume based payments $ 33,301 Simulation Discount Rate 6.4 % 6.4 % Earnout Discount Rate 5.9 %- 6.1 % 6.0 % Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Disaggregation of Revenue	Revenues for the three months ended March 31, 2023 and 2022 were as follows: Three Months Ended 2023 2022 (Amounts in thousands) Product revenue $ 182,621 $ 206,363 Royalty and other income 39 37 Total revenue $ 182,660 $ 206,400
Summary of Receivables and Deferred Revenue from Contracts with Customers	The following table provides information about receivables and deferred revenue from contracts with customers as of March 31, 2023 (amounts in thousands): March 31, December 31, 2023 2022 Balances from contracts with customers only: Accounts receivable $ 133,488 $ 116,247 Deferred revenue (included in accrued liabilities and $ 18,821 $ 19,631 Revenue recognized during periods presented relating to: The beginning deferred revenue balance $ 8,601 $ 13,390

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill And Other Intangible Assets Disclosure [Abstract]
Changes in Carrying Value of Goodwill	The following table represents the change in the carrying value of goodwill for the three months ended March 31, 2023 (amounts in thousands): Balance at December 31, 2022 $ 855,513 Cumulative translation adjustment 788 Balance at March 31, 2023 $ 856,301
Schedule of Intangible Assets	Intangible assets, net, consisted of the following at March 31, 2023: March 31, 2023 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology - developed $ 190,620 $ ( 33,983 ) $ 156,637 16 Patents 240 ( 240 ) — 8 Customer relationships 253,181 ( 70,844 ) 182,337 16 Trademarks 7,687 ( 1,431 ) 6,256 19 Other intangibles 2,819 ( 2,154 ) 665 4 Total finite-lived intangible assets 454,547 ( 108,652 ) 345,895 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 455,247 $ ( 108,652 ) $ 346,595 Intangible assets, net, consisted of the following at December 31, 2022: December 31, 2022 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology - developed $ 190,463 $ ( 30,992 ) $ 159,471 16 Patents 240 ( 240 ) — 8 Customer relationships 252,934 ( 66,559 ) 186,375 15 Trademarks 7,682 ( 1,319 ) 6,363 19 Other intangibles 2,811 ( 2,044 ) 767 4 Total finite-lived intangible assets 454,130 ( 101,154 ) 352,976 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 454,830 $ ( 101,154 ) $ 353,676
Schedule of Amortization Expense for Amortized Intangible Assets	As of March 31, 2023, the Company expects to record the following amortization expense in future periods (amounts in thousands): Estimated Amortization For the Years Ended December 31, Expense 2023 (remaining nine months) $ 22,073 2024 28,628 2025 28,370 2026 28,388 2027 28,302 2028 and thereafter 210,134 Total $ 345,895

Consolidated Balance Sheet De_2

Consolidated Balance Sheet Detail (Tables)	3 Months Ended
	Mar. 31, 2023
Disclosure Text Block [Abstract]
Inventories	Inventories, net Inventories, net consists of the following: March 31, December 31, 2023 2022 (Amounts in thousands) Raw materials $ 150,398 $ 149,438 Work-in-process 6,277 6,183 Finished products 88,029 82,656 Total inventories, net $ 244,704 $ 238,277
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment consist of the following: March 31, December 31, 2023 2022 (Amounts in thousands) Land $ 1,006 $ 1,003 Buildings 1,657 1,599 Leasehold improvements 120,361 115,672 Equipment 99,051 94,613 Furniture, fixtures and office equipment 8,447 8,307 Computer hardware and software 31,226 29,813 Construction in progress 30,891 31,553 Other 429 420 Total property, plant and equipment 293,068 282,980 Less - Accumulated depreciation ( 100,376 ) ( 92,307 ) Total property, plant and equipment, net $ 192,692 $ 190,673
Accrued Liabilities	Accrued Liabilities Accrued liabilities consist of the following: March 31, December 31, 2023 2022 (Amounts in thousands) Employee compensation $ 20,592 $ 33,522 Deferred revenue 18,378 19,283 Income taxes payable 2,747 2,459 Other 16,338 15,856 Total accrued liabilities $ 58,055 $ 71,120

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Carrying Value of Convertible Senior Notes	The net carrying value of the liability component of the 2019 Notes is as follows: March 31, December 31, (Amounts in thousands) 0.375% Convertible Senior Notes due 2024: Principal amount $ 287,470 $ 287,470 Unamortized debt issuance costs ( 2,398 ) ( 2,855 ) Net carrying amount $ 285,072 $ 284,615
Schedule of convertiable note interest expense	The following table sets forth total interest expense recognized related to the 2019 Notes: Three Months Ended 2023 2022 (Amounts in thousands) Contractual interest expense $ 270 $ 270 Amortization of debt issuance costs 457 452 Total $ 727 $ 722 Effective interest rate of the liability component 1 % 1 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stock-Based Compensation Expense	The following table presents stock-based compensation expense in the Company’s condensed consolidated statements of comprehensive income: Three Months Ended 2023 2022 (Amounts in thousands) Cost of product revenue $ 591 $ 622 Research and development 787 799 Selling, general and administrative 5,876 6,494 Total stock-based compensation $ 7,254 $ 7,915
Summary of Option Activity	Information regarding option activity for the three months ended March 31, 2023 under the Plans is summarized below: Shares Weighted Weighted- Aggregate Options outstanding at December 31, 2022 609,965 $ 71.74 Granted 42,982 $ 181.03 Exercised ( 1,300 ) $ 22.41 Forfeited/expired/cancelled ( 2,000 ) $ 199.71 Options outstanding at March 31, 2023 649,647 $ 78.68 Options exercisable at March 31, 2023 374,084 $ 54.57 Vested and expected to vest at March 31, 2023 (1) 633,533 $ 78.10 5.91 $ 60,647 (1) Represents the number of vested options as of March 31, 2023 plus the number of unvested options expected to vest as of March 31, 2023 based on the unvested outstanding options at March 31, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.
Summary of Restricted Stock Unit Activity	Information regarding stock unit activity, which includes activity for RSUs and performance stock units, for the three months ended March 31, 2023 under the Plans is summarized below: Shares Weighted Average Unvested at December 31, 2022 531,034 $ 142.57 Awarded 130,929 $ 180.05 Vested ( 123,938 ) $ 118.33 Forfeited/cancelled ( 21,529 ) $ 195.74 Unvested at March 31, 2023 516,496 $ 154.72 Vested and expected to vest at March 31, 2023 (1) 479,766 $ 153.33 Represents the number of vested stock units as of March 31, 2023 plus the number of unvested stock units expected to vest as of March 31, 2023 based on the unvested outstanding stock units at March 31, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share, Basic [Abstract]
Basic and Diluted Weighted Average Shares Outstanding	A reconciliation of basic and diluted weighted average shares outstanding is as follows: Three Months Ended 2023 2022 (Amounts in thousands, Numerator: Net income $ 28,829 $ 46,964 Effect of dilutive securities: Charges associated with convertible debt instruments, net of tax — 387 Numerator for diluted earnings per share - net income available to common $ 28,829 $ 47,351 Denominator: Weighted average shares used in computing net income per share - basic 55,590 55,353 Effect of dilutive shares: Options and stock units 529 726 Convertible senior notes 883 2,726 Contingent consideration 44 — Dilutive effect of unvested performance stock units 3 11 Dilutive potential common shares 1,459 3,463 Denominator for diluted earnings per share - adjusted weighted average 57,049 58,816 Earnings per share: Basic $ 0.52 $ 0.85 Diluted $ 0.51 $ 0.81

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2023
Text Block [Abstract]
Percentage by Geographic Area or Significant Customers	The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended March 31, 2023 2022 Revenue by customers' geographic locations: North America 38 % 40 % Europe 39 % 43 % APAC/Other 23 % 17 % Total revenue 100 % 100 %

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Company's Cash, Cash Equivalents and Marketable Securities Held to Maturity (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Cash and money market funds
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Costs	$ 516,609	$ 523,458
Cash and cash equivalents, Estimated Fair Value	516,609	523,458
Cash and cash equivalents
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents, Amortized Costs	516,609	523,458
Cash and cash equivalents, Estimated Fair Value	516,609	523,458
U.S. treasury bills
Cash and Cash Equivalents [Line Items]
Marketable securities, Amortized Costs	101,409	100,299
Marketable securities, Gross Unrealized Gains	58	24
Marketable securities, Estimated Fair Value	101,467	100,323
Cash equivalents and marketable securities
Cash and Cash Equivalents [Line Items]
Marketable securities, Amortized Costs	618,018	623,757
Marketable securities, Gross Unrealized Gains	58	24
Marketable securities, Estimated Fair Value	$ 618,076	$ 623,781

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Amortized Cost and Fair Value Held to Maturity Securities by Contractual Maturity (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Maturity of one year or less, Amortized Costs	$ 101,409	$ 100,299
Total, Amortized Costs	101,409	100,299
Maturity of one year or less, Estimated Fair Value	101,467	100,323
Total, Estimated Fair Value	$ 101,467	$ 100,323

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Financial assets and financial liabilities measured at fair value on a recurring basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023		Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term contingent consideration	$ 27,834	[1]	$ 13,950
Long-term contingent consideration	38,910		51,559
Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	339,044		343,929
Level 1 | Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	339,044		343,929
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term contingent consideration	27,834	[1]	13,950
Long-term contingent consideration	$ 38,910		$ 51,559
[1] The $ 27.8 million of short-term contingent consideration includes $ 14.5 million due and payable to the remaining securityholders of Avitide related to the First Earnout Year as defined in the Agreement and Plan of Merger and Reorganization with Avalon Merger Sub, Inc., which the Company entered into as part of the acquisition of Avitide in 2021. This amount is anticipated to be paid in the second quarter of 2023.

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Financial assets and financial liabilities measured at fair value on a recurring basis (Parenthetical) (Detail) - USD ($) $ in Thousands	Mar. 31, 2023		Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term contingent consideration	$ 27,834	[1]	$ 13,950
Avitide, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term contingent consideration due	$ 14,500
[1] The $ 27.8 million of short-term contingent consideration includes $ 14.5 million due and payable to the remaining securityholders of Avitide related to the First Earnout Year as defined in the Agreement and Plan of Merger and Reorganization with Avalon Merger Sub, Inc., which the Company entered into as part of the acquisition of Avitide in 2021. This amount is anticipated to be paid in the second quarter of 2023.

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Summary Of Significant Accounting Policies [Line Items]
Purchase of treasury stock		$ 100
Avitide, Inc.
Summary Of Significant Accounting Policies [Line Items]
Business combination contingent consideration	$ 125

Fair Value Measurements - Sch_4

Fair Value Measurements - Schedule of Reconciliation of the Change in the Fair Value of Contingent Consideration - Earnout (Detail) - Contingent Consideration $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of December 31, 2021	$ 65,509
Increase in fair value of contingent consideration earnouts	1,235
Balance as of June 30 , 2022	$ 66,744

Fair Value Measurements - Sch_5

Fair Value Measurements - Schedule of Contingent Consideration Earnout Expect to be Required to Settle Include Significant Unobservable Inputs (Detail) - Contingent Consideration - USD ($) $ in Thousands		Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 66,744	$ 65,509
Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Probability of success		100%
R&D and Commercialization-based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 18,974
R&D and Commercialization-based Payments | Monte Carlo Simulation | Fair Value, Recurring | Probability of Success
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	100%
R&D and Commercialization-based Payments | Monte Carlo Simulation | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	6%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 33,301
Volatility		23.60%
Revenue and volume discount rate		6.40%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	6%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	23.60%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Revenue & Volume Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	6.40%
Minimum | R&D and Commercialization-based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		5.90%
Minimum | Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		5.90%
Maximum | R&D and Commercialization-based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.10%
Maximum | Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		6.10%
[1] Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.

Revenue Recognition - Summary o

Revenue Recognition - Summary of Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 182,660	$ 206,400	$ 206,400
Product Revenue
Disaggregation of Revenue [Line Items]
Total revenue	182,621	206,363	206,363
Royalty and Other Income
Disaggregation of Revenue [Line Items]
Total revenue	$ 39	$ 37	$ 37

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Balances from contracts with customers only:
Accounts receivable	$ 133,488	$ 116,247
Deferred revenue (included in accrued liabilities and other noncurrent liabilities in the condensed consolidated balance sheets)	18,821	19,631
Revenue recognized during periods presented relating to:
The beginning deferred revenue balance	$ 8,601	$ 13,390

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Changes in Carrying Value of Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill [Line Items]
Balance	$ 855,513
Cumulative translation adjustment	788
Balance	$ 856,301

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Finite-Lived Intangible Liabilities [Line Items]
Impairment of intangible assets	$ 0
Amortization of Intangible Assets	$ 7.4	$ 6.6

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Intangible Assets [Line Items]
Gross Carrying Value	$ 454,547	$ 454,130
Gross Carrying Value	455,247	454,830
Accumulated Amortization	(108,652)	(101,154)
Accumulated Amortization	(108,652)	(101,154)
Net Carrying Value	345,895	352,976
Net Carrying Value	$ 346,595	$ 353,676
Weighted Average Useful Life (in years)	16 years	16 years
Trademark
Intangible Assets [Line Items]
Gross Carrying Value	$ 700	$ 700
Net Carrying Value	700	700
Technology - developed
Intangible Assets [Line Items]
Gross Carrying Value	190,620	190,463
Accumulated Amortization	(33,983)	(30,992)
Net Carrying Value	$ 156,637	$ 159,471
Weighted Average Useful Life (in years)	16 years	16 years
Patents
Intangible Assets [Line Items]
Gross Carrying Value	$ 240	$ 240
Accumulated Amortization	(240)	(240)
Net Carrying Value	$ 0	$ 0
Weighted Average Useful Life (in years)	8 years	8 years
Customer relationships
Intangible Assets [Line Items]
Gross Carrying Value	$ 253,181	$ 252,934
Accumulated Amortization	(70,844)	(66,559)
Net Carrying Value	$ 182,337	$ 186,375
Weighted Average Useful Life (in years)	16 years	15 years
Trademarks
Intangible Assets [Line Items]
Gross Carrying Value	$ 7,687	$ 7,682
Accumulated Amortization	(1,431)	(1,319)
Net Carrying Value	$ 6,256	$ 6,363
Weighted Average Useful Life (in years)	19 years	19 years
Other intangibles
Intangible Assets [Line Items]
Gross Carrying Value	$ 2,819	$ 2,811
Accumulated Amortization	(2,154)	(2,044)
Net Carrying Value	$ 665	$ 767
Weighted Average Useful Life (in years)	4 years	4 years

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Amortization Expense for Amortized Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Liabilities [Line Items]
2023 (remaining nine months)	$ 22,073
2024	28,628
2025	28,370
2026	28,388
2027	28,302
2028 and thereafter	210,134
Total	$ 345,895	$ 352,976

Consolidated Balance Sheet De_3

Consolidated Balance Sheet Detail - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory [Line Items]
Raw materials	$ 150,398	$ 149,438
Work-in-process	6,277	6,183
Finished products	88,029	82,656
Total inventories, net	$ 244,704	$ 238,277

Consolidated Balance Sheet De_4

Consolidated Balance Sheet Detail - Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Land	$ 1,006	$ 1,003
Buildings	1,657	1,599
Leasehold improvements	120,361	115,672
Equipment	99,051	94,613
Furniture, fixtures and office equipment	8,447	8,307
Computer hardware and software	31,226	29,813
Construction in progress	30,891	31,553
Other	429	420
Total property, plant and equipment	293,068	282,980
Less - Accumulated depreciation	(100,376)	(92,307)
Total property, plant and equipment, net	$ 192,692	$ 190,673

Consolidated Balance Sheet De_5

Consolidated Balance Sheet Detail - Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Schedule of Accrued Liabilities [Line Items]
Employee compensation	$ 20,592	$ 33,522
Deferred revenue	18,378	19,283
Income taxes payable	2,747	2,459
Other	16,338	15,856
Total accrued liabilities	$ 58,055	$ 71,120

Convertible Senior Notes - Addi

Convertible Senior Notes - Additional Information (Detail) $ in Thousands		3 Months Ended
	Jul. 19, 2019 USD ($)	Mar. 31, 2023 USD ($) Days	Dec. 31, 2022 USD ($)	Jul. 31, 2019 USD ($)
Debt Instrument [Line Items]
Debt Instrument, Convertible, Threshold Trading Days | Days		20
Debt Instrument, Convertible, Threshold Consecutive Trading Days | Days		30
0.375% Convertible Senior Notes due 2024
Debt Instrument [Line Items]
Notes issued	$ 287,500			$ 287,500
Notes, interest rate	0.375%
Proceeds from issuance of convertible senior notes, net of costs	$ 278,500
Interest repayment terms		Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020.
Notes, due date		Jul. 15, 2024
Notes, carrying value		$ 285,072	$ 284,615
Fair value of the note		441,800	$ 452,000
Additional Notes issued	$ 37,500
Debt instrument amount convertible into equity		39,000
Loss on conversion of debt included in other expenses		$ 9,000
Notes threshold percentage of stock price trigger		130%

Convertible Senior Notes - Conv

Convertible Senior Notes - Convertible Debt (Detail) - 0.375% Convertible Senior Notes due 2024 - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal amount	$ 287,470	$ 287,470
Unamortized debt issuance costs	(2,398)	(2,855)
Total convertible senior notes	$ 285,072	$ 284,615

Convertible Senior Notes - Sche

Convertible Senior Notes - Schedule of convertiable note interest expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Debt Disclosure [Abstract]
Contractual interest expense	$ 270	$ 270
Amortization of debt issuance costs	457	452
Total	$ 727	$ 722
Debt Instrument, Interest Rate, Effective Percentage	1%	1%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2018
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation	$ 7,254	$ 7,915
Stock options, outstanding	649,647		609,965
Restricted stock units, outstanding	516,496		531,034
Aggregate intrinsic value of stock options exercised	$ 200	$ 1,400
Weighted average grant date fair value of share-based awards granted	$ 89.25	$ 79.96
Weighted average grant date fair value of restricted stock units granted	$ 180.05
Total unrecognized compensation cost	$ 81,400
Unrecognized compensation cost, weighted average remaining requisite service period	3 years 25 days
Number of unvested options and restricted stock units	2,166,862
2018 Plan
Stockholders Equity Note Disclosure [Line Items]
Common stock shares reserved for Issuance					2,778,000
Incentive options, vesting period				1,739,335
Unvested Options
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period	5 years
Restricted Stock Units and Performance Stock Units
Stockholders Equity Note Disclosure [Line Items]
Aggregate intrinsic value of restricted stock units vested	$ 24,300	$ 30,200
Weighted average grant date fair value of restricted stock units granted	$ 180.05	$ 196.36
RestrictedStockUnitsRSUMember
Stockholders Equity Note Disclosure [Line Items]
Closing price of common stock	$ 168.36

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 7,254	$ 7,915
Cost of product revenue
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	591	622
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	787	799
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 5,876	$ 6,494

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Option Activity (Detail) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Options Outstanding
Options outstanding at December 31, 2021| shares | shares	609,965
Granted | shares | shares	42,982
Exercised | shares | shares	(1,300)
Forfeited/expired/cancelled | shares	(2,000)
Options outstanding at September 30, 2022 | shares | shares	649,647
Options exercisable at September 30, 2022 | shares | shares	374,084
Vested and expected to vest at September 30, 2022 (1) | shares | shares	633,533	[1]
Weighted-Average Exercise Price Per Share
Options outstanding at December 31, 2021 | $ / shares	$ 71.74
Granted | $ / shares	181.03
Exercised | $ / shares	22.41
Forfeited/expired/cancelled | $ / shares	199.71
Options outstanding at September 30, 2022 | $ / shares	78.68
Options exercisable at September 30, 2022 | $ / shares	54.57
Vested and expected to vest at March 31, 2023 | $ / shares	$ 78.10	[1]
Weighted-Average Remaining Contractual Term (in years)
Vested and expected to vest at September 30, 2022	5 years 10 months 28 days	[1]
Aggregate Intrinsic Value
Vested and expected to vest at September 30, 2022 | $	$ 60,647	[1]
[1] Represents the number of vested options as of March 31, 2023 plus the number of unvested options expected to vest as of March 31, 2023 based on the unvested outstanding options at March 31, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Option Activity (Parenthetical) (Detail) - Employee Stock Option	Mar. 31, 2023
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3%

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail) - $ / shares		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Options Outstanding
Unvested at December 31, 2022		531,034
Awarded		130,929
Vested		(123,938)
Forfeited/expired/cancelled		(21,529)
Unvested at March 31, 2023		516,496
Vested and expected to vest at March 31, 2023	[1]	479,766
Weighted-Average Remaining Contractual Term (in years)
Weighted Average, Unvested at December 31,2022		$ 142.57
Weighted Average, Awarded		180.05
Weighted Average, Vested		118.33
Weighted Average, Forfeited/Cancelled		195.74
Weighted Average, Unvested at March 31, 2023		154.72
Weighted Average, Vested and expected to vest at March 31, 2023	[1]	153.33
Restricted Stock Units and Performance Stock Units
Weighted-Average Remaining Contractual Term (in years)
Weighted Average, Awarded		$ 180.05	$ 196.36
[1] Represents the number of vested stock units as of March 31, 2023 plus the number of unvested stock units expected to vest as of March 31, 2023 based on the unvested outstanding stock units at March 31, 2023 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Stockholders' Equity - Summar_4

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Parenthetical) (Detail) - Restricted Stock Units and Performance Stock Units	Mar. 31, 2023
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
NGL Impact A [Member] | Research and Development Arrangement [Member]
Commitments and Contingencies [Line Items]
Payments to Navigo in connection with this program, which are recorded to research and development expenses	$ 1.1	$ 0.4

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended
	Aug. 16, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Taxes [Line Items]
Income tax provision		$ 7,263	$ 11,967
Income tax (benefit) provision		20.10%	20.30%
Inflation Reduction Act Of Two Thousand Twenty Two [Member]
Income Taxes [Line Items]
Percentage of alternative minimum tax	15%
Percent of excise tax on net stock repurchases	1%

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	Mar. 04, 2022	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2022	Jul. 31, 2019	Jul. 19, 2019
Stock options, outstanding		649,647			609,965
Stock options, weighted average exercise price		$ 78.68			$ 71.74
Restricted stock units, outstanding		516,496			531,034
Common stock excluded from calculation of diluted earnings per share		263,871		137,247
Dilutive effect on shares of conversion premium			882,599	2,726,258
Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted		57,049		58,816
Charges associated with convertible debt instruments, net of tax		$ 0		$ 387
AccountingStandardsUpdate202006Member
Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted	3,474,429
Charges associated with convertible debt instruments, net of tax				$ 400
0.375% Convertible Senior Notes due 2024
Principal amount						$ 287,500	$ 287,500

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Basic and Diluted Shares Amounts (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator
Net income	$ 28,829	$ 46,964
Effect of dilutive securities
Charges associated with convertible debt instruments, net of tax	0	387
Numerator for diluted earnings per share - net income available to common stockholders after the effect of dilutive securities	$ 28,829	$ 47,351
Denominator
Weighted average shares used in computing net income per share - basic	55,590	55,353
Effect of dilutive shares
Options and stock units	529	726
Convertible senior notes	883	2,726
Contingent consideration	44	0
Dilutive effect of unvested performance stock units	3	11
Dilutive potential common shares	1,459	3,463
Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted	57,049	58,816
Earnings per share:
Basic	$ 0.52	$ 0.85
Diluted (Note 10)	$ 0.51	$ 0.81

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Principal Owner - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Related Party Transaction [Line Items]
Spectrum Acquisition, tax preparation and other fees	$ 0.2	$ 0.2
Minimum | Spectrum Inc.
Related Party Transaction [Line Items]
Non controlling ownership interest minimum	5%

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023 USD ($) Segment	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Number of operating segments | Segment	1
Accounts receivable, percentage by customer	100%	100%
Revenue	$ 182,660	$ 206,400	$ 206,400
Customer Concentration Risk | Pfizer [Member]
Revenue	$ 20,100	$ 21,100
Customer Concentration Risk | Sales Revenue | Pfizer [Member]
Accounts receivable, percentage by customer	11%	10.20%
Customer Concentration Risk | Accounts Receivable [Member] | Pfizer [Member]
Accounts receivable, percentage by customer	14.70%
Customer Concentration Risk | Accounts Receivable [Member] | Purolite [Member]
Accounts receivable, percentage by customer			12.70%
Customer Concentration Risk | Total Trade Accounts Receivable Royalties And Other Receivables | Pfizer [Member]
Accounts receivable, percentage by customer	10%
Customer Concentration Risk | Total Trade Accounts Receivable Royalties And Other Receivables | Purolite [Member]
Accounts receivable, percentage by customer			10%

Segment Reporting - Percentage

Segment Reporting - Percentage of Revenue by Geographic Area (Detail)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Concentration Risk [Line Items]
Revenues, percentage by country	100%	100%
Geographic Concentration Risk | Total Revenue | North America
Concentration Risk [Line Items]
Revenues, percentage by country	38%	40%
Geographic Concentration Risk | Total Revenue | Europe
Concentration Risk [Line Items]
Revenues, percentage by country	39%	43%
Geographic Concentration Risk | Total Revenue | APAC/Other
Concentration Risk [Line Items]
Revenues, percentage by country	23%	17%

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail)	Apr. 17, 2023
Subsequent Event | FlexBiosys, Inc.
Subsequent Event [Line Items]
Business combination date of acquistion	Apr. 17, 2023